MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis

M. P. Martelli, M. Martelli, E. Pescarmona, V. De Sanctis, V. Donato, F. Palombi, E. Todisco, E. A. Rendina, F. M. Pau, F. Mandelli

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the clinical features of presentation and the response to two different third-generation regimens (F-MACHOP and MACOP-B) of primary mediastinal large B-cell lymphoma (MLBCL), a recently defined distinct clinicopathological entity of non-Hodgkin's lymphoma (NHL). Patients and methods: Thirty-seven consecutive patients with MLBCL, eight male and 29 female (F/M ratio 1:3.5) with a median age of 35 years, were enrolled in the present study. Thirty-five (94.5%) patients presented disease confined to thorax, with chest symptoms of a rapidly enlarging mass in the mediastinum in 70% and superior vena cava syndrome (SCVS) in 43% of these patients. The first 10 patients received F-MACHOP and the succeeding 27 patients MACOP-B chemotherapy, associated in 24 (88.8%) with involved field radiation therapy (IFRT). Gallium scan was routinely performed pre- and post- IFRT in 18 patients. Results: All 37 patients were assessable for response: 10 of 10 (100%) in the F-MACHOP and 26 of 27 (96.3%) in the MACOP-B group achieved overall responses (CR+PR). Three of 24 (12.5%) patients in PR after chemotherapy obtained CR after IFRT. Persistent Gallium avidity was observed in 16 patients after chemotherapy and in only four patients after IFRT. Thus far, four of the 10 F-MACHOP and two of the 26 MACOP-B responders have presented disease progression. The probability of progression-free survival (PFS) was 91% and 60% (P <0.02) while overall survival (OS) was 93% and 70% (P = n.s.) at a mean follow-up of 27 and 52 months in the MACOP-B+IFRT and F-MACHOP groups, respectively. Conclusion: MACOP-B+IFRT has proved to be a highly effective and less toxic therapeutic approach for primary MLBCL and appears to be superior to other third-generation chemotherapy regimens.

Original languageEnglish
Pages (from-to)1027-1029
Number of pages3
JournalAnnals of Oncology
Volume9
Issue number9
DOIs
Publication statusPublished - Sep 1998

Fingerprint

Sclerosis
B-Cell Lymphoma
Radiotherapy
Therapeutics
Drug Therapy
Gallium
Thorax
Superior Vena Cava Syndrome
Poisons
Mediastinum
Non-Hodgkin's Lymphoma
Disease-Free Survival
Disease Progression

Keywords

  • Chemotherapy
  • Mediastinum
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Martelli, M. P., Martelli, M., Pescarmona, E., De Sanctis, V., Donato, V., Palombi, F., ... Mandelli, F. (1998). MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. Annals of Oncology, 9(9), 1027-1029. https://doi.org/10.1023/A:1008412009667

MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. / Martelli, M. P.; Martelli, M.; Pescarmona, E.; De Sanctis, V.; Donato, V.; Palombi, F.; Todisco, E.; Rendina, E. A.; Pau, F. M.; Mandelli, F.

In: Annals of Oncology, Vol. 9, No. 9, 09.1998, p. 1027-1029.

Research output: Contribution to journalArticle

Martelli, MP, Martelli, M, Pescarmona, E, De Sanctis, V, Donato, V, Palombi, F, Todisco, E, Rendina, EA, Pau, FM & Mandelli, F 1998, 'MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis', Annals of Oncology, vol. 9, no. 9, pp. 1027-1029. https://doi.org/10.1023/A:1008412009667
Martelli, M. P. ; Martelli, M. ; Pescarmona, E. ; De Sanctis, V. ; Donato, V. ; Palombi, F. ; Todisco, E. ; Rendina, E. A. ; Pau, F. M. ; Mandelli, F. / MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. In: Annals of Oncology. 1998 ; Vol. 9, No. 9. pp. 1027-1029.
@article{5a3a99f6097c4104939e1fb2d10323d0,
title = "MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis",
abstract = "Purpose: To evaluate the clinical features of presentation and the response to two different third-generation regimens (F-MACHOP and MACOP-B) of primary mediastinal large B-cell lymphoma (MLBCL), a recently defined distinct clinicopathological entity of non-Hodgkin's lymphoma (NHL). Patients and methods: Thirty-seven consecutive patients with MLBCL, eight male and 29 female (F/M ratio 1:3.5) with a median age of 35 years, were enrolled in the present study. Thirty-five (94.5{\%}) patients presented disease confined to thorax, with chest symptoms of a rapidly enlarging mass in the mediastinum in 70{\%} and superior vena cava syndrome (SCVS) in 43{\%} of these patients. The first 10 patients received F-MACHOP and the succeeding 27 patients MACOP-B chemotherapy, associated in 24 (88.8{\%}) with involved field radiation therapy (IFRT). Gallium scan was routinely performed pre- and post- IFRT in 18 patients. Results: All 37 patients were assessable for response: 10 of 10 (100{\%}) in the F-MACHOP and 26 of 27 (96.3{\%}) in the MACOP-B group achieved overall responses (CR+PR). Three of 24 (12.5{\%}) patients in PR after chemotherapy obtained CR after IFRT. Persistent Gallium avidity was observed in 16 patients after chemotherapy and in only four patients after IFRT. Thus far, four of the 10 F-MACHOP and two of the 26 MACOP-B responders have presented disease progression. The probability of progression-free survival (PFS) was 91{\%} and 60{\%} (P <0.02) while overall survival (OS) was 93{\%} and 70{\%} (P = n.s.) at a mean follow-up of 27 and 52 months in the MACOP-B+IFRT and F-MACHOP groups, respectively. Conclusion: MACOP-B+IFRT has proved to be a highly effective and less toxic therapeutic approach for primary MLBCL and appears to be superior to other third-generation chemotherapy regimens.",
keywords = "Chemotherapy, Mediastinum, Non-Hodgkin's lymphoma",
author = "Martelli, {M. P.} and M. Martelli and E. Pescarmona and {De Sanctis}, V. and V. Donato and F. Palombi and E. Todisco and Rendina, {E. A.} and Pau, {F. M.} and F. Mandelli",
year = "1998",
month = "9",
doi = "10.1023/A:1008412009667",
language = "English",
volume = "9",
pages = "1027--1029",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "9",

}

TY - JOUR

T1 - MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis

AU - Martelli, M. P.

AU - Martelli, M.

AU - Pescarmona, E.

AU - De Sanctis, V.

AU - Donato, V.

AU - Palombi, F.

AU - Todisco, E.

AU - Rendina, E. A.

AU - Pau, F. M.

AU - Mandelli, F.

PY - 1998/9

Y1 - 1998/9

N2 - Purpose: To evaluate the clinical features of presentation and the response to two different third-generation regimens (F-MACHOP and MACOP-B) of primary mediastinal large B-cell lymphoma (MLBCL), a recently defined distinct clinicopathological entity of non-Hodgkin's lymphoma (NHL). Patients and methods: Thirty-seven consecutive patients with MLBCL, eight male and 29 female (F/M ratio 1:3.5) with a median age of 35 years, were enrolled in the present study. Thirty-five (94.5%) patients presented disease confined to thorax, with chest symptoms of a rapidly enlarging mass in the mediastinum in 70% and superior vena cava syndrome (SCVS) in 43% of these patients. The first 10 patients received F-MACHOP and the succeeding 27 patients MACOP-B chemotherapy, associated in 24 (88.8%) with involved field radiation therapy (IFRT). Gallium scan was routinely performed pre- and post- IFRT in 18 patients. Results: All 37 patients were assessable for response: 10 of 10 (100%) in the F-MACHOP and 26 of 27 (96.3%) in the MACOP-B group achieved overall responses (CR+PR). Three of 24 (12.5%) patients in PR after chemotherapy obtained CR after IFRT. Persistent Gallium avidity was observed in 16 patients after chemotherapy and in only four patients after IFRT. Thus far, four of the 10 F-MACHOP and two of the 26 MACOP-B responders have presented disease progression. The probability of progression-free survival (PFS) was 91% and 60% (P <0.02) while overall survival (OS) was 93% and 70% (P = n.s.) at a mean follow-up of 27 and 52 months in the MACOP-B+IFRT and F-MACHOP groups, respectively. Conclusion: MACOP-B+IFRT has proved to be a highly effective and less toxic therapeutic approach for primary MLBCL and appears to be superior to other third-generation chemotherapy regimens.

AB - Purpose: To evaluate the clinical features of presentation and the response to two different third-generation regimens (F-MACHOP and MACOP-B) of primary mediastinal large B-cell lymphoma (MLBCL), a recently defined distinct clinicopathological entity of non-Hodgkin's lymphoma (NHL). Patients and methods: Thirty-seven consecutive patients with MLBCL, eight male and 29 female (F/M ratio 1:3.5) with a median age of 35 years, were enrolled in the present study. Thirty-five (94.5%) patients presented disease confined to thorax, with chest symptoms of a rapidly enlarging mass in the mediastinum in 70% and superior vena cava syndrome (SCVS) in 43% of these patients. The first 10 patients received F-MACHOP and the succeeding 27 patients MACOP-B chemotherapy, associated in 24 (88.8%) with involved field radiation therapy (IFRT). Gallium scan was routinely performed pre- and post- IFRT in 18 patients. Results: All 37 patients were assessable for response: 10 of 10 (100%) in the F-MACHOP and 26 of 27 (96.3%) in the MACOP-B group achieved overall responses (CR+PR). Three of 24 (12.5%) patients in PR after chemotherapy obtained CR after IFRT. Persistent Gallium avidity was observed in 16 patients after chemotherapy and in only four patients after IFRT. Thus far, four of the 10 F-MACHOP and two of the 26 MACOP-B responders have presented disease progression. The probability of progression-free survival (PFS) was 91% and 60% (P <0.02) while overall survival (OS) was 93% and 70% (P = n.s.) at a mean follow-up of 27 and 52 months in the MACOP-B+IFRT and F-MACHOP groups, respectively. Conclusion: MACOP-B+IFRT has proved to be a highly effective and less toxic therapeutic approach for primary MLBCL and appears to be superior to other third-generation chemotherapy regimens.

KW - Chemotherapy

KW - Mediastinum

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0031791389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031791389&partnerID=8YFLogxK

U2 - 10.1023/A:1008412009667

DO - 10.1023/A:1008412009667

M3 - Article

C2 - 9818079

AN - SCOPUS:0031791389

VL - 9

SP - 1027

EP - 1029

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -